Factor XIII and atherothrombotic diseases

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Factor XIII (FXIII) is a protransglutaminase that, after activation, cross-links fibrin chains and several plasma proteins, most importantly plasmin inhibitor, to fibrin. FXIII strengthens the fibrin clot by covalent bonds and protects fibrin from the prompt elimination by the fibrinolytic system. In the last two decades, FXIII has emerged as a key regulator of fibrinolysis. FXIII is also present in platelets, monocytes, and macrophages, but this cellular form does not contribute significantly to maintaining hemostasis. FXIII deficiency is a life-threatening bleeding diathesis whose clinical consequences are well studied. In contrast, the involvement of FXIII in thrombotic disorders and its association with the risk of such diseases are less clear. This review gives an account of the data accumulated mainly in the last decade on the association of FXIII with atherothrombotic diseases and presents conclusions and hypotheses drawn from these data as well as exposing the limitations of the published studies and our knowledge on this topic. The involvement of FXIII in atherogenesis, its role in coronary artery disease, atherothrombotic ischemic stroke, and peripheral artery disease are discussed, with particular reference to the association of FXIII levels and polymorphisms with the risk of these diseases.

Original languageEnglish
Pages (from-to)18-33
Number of pages16
JournalSeminars in Thrombosis and Hemostasis
Volume36
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Factor XIII
Fibrin
Factor XIII Deficiency
Antifibrinolytic Agents
Peripheral Arterial Disease
Disease Susceptibility
Fibrinolysis
Hemostasis
Blood Proteins
Coronary Artery Disease
Monocytes
Atherosclerosis
Blood Platelets
Stroke
Macrophages
Hemorrhage

Keywords

  • Cardiovascular disease
  • Factor XIII
  • Factor XIII ploymorphisms
  • Peripheral artery disease
  • Stroke

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Factor XIII and atherothrombotic diseases. / Muszbek, L.; Bereczky, Z.; Bagoly, Z.; Shemirani, Amir H.; Katona, E.

In: Seminars in Thrombosis and Hemostasis, Vol. 36, No. 1, 2010, p. 18-33.

Research output: Contribution to journalArticle

@article{debcf814bebc498190d6547e0b7c98cc,
title = "Factor XIII and atherothrombotic diseases",
abstract = "Factor XIII (FXIII) is a protransglutaminase that, after activation, cross-links fibrin chains and several plasma proteins, most importantly plasmin inhibitor, to fibrin. FXIII strengthens the fibrin clot by covalent bonds and protects fibrin from the prompt elimination by the fibrinolytic system. In the last two decades, FXIII has emerged as a key regulator of fibrinolysis. FXIII is also present in platelets, monocytes, and macrophages, but this cellular form does not contribute significantly to maintaining hemostasis. FXIII deficiency is a life-threatening bleeding diathesis whose clinical consequences are well studied. In contrast, the involvement of FXIII in thrombotic disorders and its association with the risk of such diseases are less clear. This review gives an account of the data accumulated mainly in the last decade on the association of FXIII with atherothrombotic diseases and presents conclusions and hypotheses drawn from these data as well as exposing the limitations of the published studies and our knowledge on this topic. The involvement of FXIII in atherogenesis, its role in coronary artery disease, atherothrombotic ischemic stroke, and peripheral artery disease are discussed, with particular reference to the association of FXIII levels and polymorphisms with the risk of these diseases.",
keywords = "Cardiovascular disease, Factor XIII, Factor XIII ploymorphisms, Peripheral artery disease, Stroke",
author = "L. Muszbek and Z. Bereczky and Z. Bagoly and Shemirani, {Amir H.} and E. Katona",
year = "2010",
doi = "10.1055/s-0030-1248721",
language = "English",
volume = "36",
pages = "18--33",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Factor XIII and atherothrombotic diseases

AU - Muszbek, L.

AU - Bereczky, Z.

AU - Bagoly, Z.

AU - Shemirani, Amir H.

AU - Katona, E.

PY - 2010

Y1 - 2010

N2 - Factor XIII (FXIII) is a protransglutaminase that, after activation, cross-links fibrin chains and several plasma proteins, most importantly plasmin inhibitor, to fibrin. FXIII strengthens the fibrin clot by covalent bonds and protects fibrin from the prompt elimination by the fibrinolytic system. In the last two decades, FXIII has emerged as a key regulator of fibrinolysis. FXIII is also present in platelets, monocytes, and macrophages, but this cellular form does not contribute significantly to maintaining hemostasis. FXIII deficiency is a life-threatening bleeding diathesis whose clinical consequences are well studied. In contrast, the involvement of FXIII in thrombotic disorders and its association with the risk of such diseases are less clear. This review gives an account of the data accumulated mainly in the last decade on the association of FXIII with atherothrombotic diseases and presents conclusions and hypotheses drawn from these data as well as exposing the limitations of the published studies and our knowledge on this topic. The involvement of FXIII in atherogenesis, its role in coronary artery disease, atherothrombotic ischemic stroke, and peripheral artery disease are discussed, with particular reference to the association of FXIII levels and polymorphisms with the risk of these diseases.

AB - Factor XIII (FXIII) is a protransglutaminase that, after activation, cross-links fibrin chains and several plasma proteins, most importantly plasmin inhibitor, to fibrin. FXIII strengthens the fibrin clot by covalent bonds and protects fibrin from the prompt elimination by the fibrinolytic system. In the last two decades, FXIII has emerged as a key regulator of fibrinolysis. FXIII is also present in platelets, monocytes, and macrophages, but this cellular form does not contribute significantly to maintaining hemostasis. FXIII deficiency is a life-threatening bleeding diathesis whose clinical consequences are well studied. In contrast, the involvement of FXIII in thrombotic disorders and its association with the risk of such diseases are less clear. This review gives an account of the data accumulated mainly in the last decade on the association of FXIII with atherothrombotic diseases and presents conclusions and hypotheses drawn from these data as well as exposing the limitations of the published studies and our knowledge on this topic. The involvement of FXIII in atherogenesis, its role in coronary artery disease, atherothrombotic ischemic stroke, and peripheral artery disease are discussed, with particular reference to the association of FXIII levels and polymorphisms with the risk of these diseases.

KW - Cardiovascular disease

KW - Factor XIII

KW - Factor XIII ploymorphisms

KW - Peripheral artery disease

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=77951071330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951071330&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1248721

DO - 10.1055/s-0030-1248721

M3 - Article

C2 - 20391293

AN - SCOPUS:77951071330

VL - 36

SP - 18

EP - 33

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 1

ER -